Individual generic drug information

salmeterol

Reference monograph

Part of registered formulation

SALMETEROL/ FLUTICASONE PROPIONATE

Reference record: Salmeterol
Source: BNF 80 (2020–2021)
Printed source pages: 288, 289
Age groups indexed: 2

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Salmeterol only.

Indications And Dose

Reversible airways obstruction in patients requiring long- term regular bronchodilator therapy | Nocturnal asthma in patients requiring long-term regular bronchodilator therapy | Prevention of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy | Chronic asthma only in patients who regularly use an inhaled corticosteroid (not for immediate relief of acute asthma) ▶BY INHALATION OF AEROSOL, OR BY INHALATION OF POWDER ▶Child 5–11 years: 50 micrograms twice daily ▶Child 12–17 years: 50 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 100 micrograms twice daily ▶Adult: 50 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 100 micrograms twice daily Chronic obstructive pulmonary disease ▶BY INHALATION OF AEROSOL, OR BY INHALATION OF POWDER ▶Adult: 50 micrograms twice daily

Source page 288

Pharmacokinetics

▶At recommended inhaled doses, the duration of action of salmeterol is about 12 hours. l UNLICENSED USE Neovent ® not licensed for use in children under 12 years.

Source page 288

Cautions

High doses of beta2 agonists can be dangerous in some children

Source page 288

Safety

Extracted information for Salmeterol only.

Important Safety Information

CHM ADVICE To ensure safe use, the CHM has advised that for the management of chronic asthma, long-acting beta2 agonist (salmeterol) should: . be added only if regular use of standard-dose inhaled corticosteroids has failed to control asthma adequately; . not be initiated in patients with rapidly deteriorating asthma; . be introduced at a low dose and the effect properly monitored before considering dose increase; . be discontinued in the absence of beneﬁt; . not be used for the relief of exercise-induced asthma symptoms unless regular inhaled corticosteroids are also used; . be reviewed as clinically appropriate: stepping down therapy should be considered when good long-term asthma control has been achieved. MHRA/CHM ADVICE: PRESSURISED METERED DOSE INHALERS (PMDI): RISK OF AIRWAY OBSTRUCTION FROM ASPIRATION OF LOOSE OBJECTS (JULY 2018) See Respiratory system, drug delivery p. 249.

Source page 288

Interactions

→Appendix 1: beta2 agonists

Source page 288

Side Effects

▶Common or very common Muscle cramps ▶Uncommon Nervousness. skin reactions ▶Rare or very rare Arthralgia. bronchospasm. chest pain. insomnia. oedema. oropharyngeal irritation

Source page 288

Pregnancy

Inhaled drugs for asthma can be taken as normal during pregnancy.

Source page 288

Breast Feeding

Inhaled drugs for asthma can be taken as normal during breast-feeding.

Source page 288

Dose and formulations

Extracted information for Salmeterol only.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Inhalation powder ▶Serevent Accuhaler (GlaxoSmithKline UK Ltd) Salmeterol (as Salmeterol xinafoate) 50 microgram per 1 dose Serevent 50micrograms/dose Accuhaler | 60 dose P £35.11 DT = £35.11 Pressurised inhalation ▶Neovent (Kent Pharmaceuticals Ltd) Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose Neovent 25micrograms/dose inhaler CFC free | 120 dose P £29.26 DT = £29.26 ▶Serevent Evohaler (GlaxoSmithKline UK Ltd) Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose Serevent 25micrograms/dose Evohaler | 120 dose P £29.26 DT = £29.26 ▶Soltel (Cipla EU Ltd) Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose Soltel 25micrograms/dose inhaler CFC free | 120 dose P £19.95 DT = £29.26 Combinations available: Fluticasone with salmeterol, p. 277 BETA2-ADRENOCEPTOR AGONISTS, SELECTIVE › SHORT-ACTING eiiii F 264

Source pages 288, 289

Clinical care

Extracted information for Salmeterol only.

Patient And Carer Advice

Advise patients that salmeterol should not be used for relief of acute attacks, not to exceed prescribed dose, and to follow manufacturer’s directions; if a previously effective dose of inhaled salmeterol fails to provide adequate relief, a doctor’s advice should be obtained as soon as possible. Patients should be advised to report any deterioration in symptoms following initiation of treatment with a long- acting beta2 agonist. Medicines for Children leaflet: Salmeterol inhaler for asthma www.medicinesforchildren.org.uk/salmeterol-inhaler-asthma

Source page 288

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Children

First line only; read the complete Indications and dose section above.

50 micrograms twice daily

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 288

Children

First line only; read the complete Indications and dose section above.

50 micrograms twice daily, dose may

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 288

Adults

First line only; read the complete Indications and dose section above.

50 micrograms twice daily, dose may be

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 288

Adults

First line only; read the complete Indications and dose section above.

50 micrograms twice daily

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 288

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

salmeterol

Reference monograph

Part of registered formulation

SALMETEROL/ FLUTICASONE PROPIONATE

Reference record: Salmeterol
Source: BNF 80 (2020–2021)
Printed source pages: 288, 289
Age groups indexed: 2

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Salmeterol only.

Indications And Dose

Source page 288

Pharmacokinetics

▶At recommended inhaled doses, the duration of action of salmeterol is about 12 hours. l UNLICENSED USE Neovent ® not licensed for use in children under 12 years.

Source page 288

Cautions

High doses of beta2 agonists can be dangerous in some children

Source page 288

Safety

Extracted information for Salmeterol only.

Important Safety Information

Source page 288

Interactions

→Appendix 1: beta2 agonists

Source page 288

Side Effects

▶Common or very common Muscle cramps ▶Uncommon Nervousness. skin reactions ▶Rare or very rare Arthralgia. bronchospasm. chest pain. insomnia. oedema. oropharyngeal irritation

Source page 288

Pregnancy

Inhaled drugs for asthma can be taken as normal during pregnancy.

Source page 288

Breast Feeding

Inhaled drugs for asthma can be taken as normal during breast-feeding.

Source page 288

Dose and formulations

Extracted information for Salmeterol only.

Medicinal Forms

Source pages 288, 289

Clinical care

Extracted information for Salmeterol only.

Patient And Carer Advice

Source page 288

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Children

First line only; read the complete Indications and dose section above.

50 micrograms twice daily

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 288

Children

First line only; read the complete Indications and dose section above.

50 micrograms twice daily, dose may

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 288

Adults

First line only; read the complete Indications and dose section above.

50 micrograms twice daily, dose may be

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 288

Adults

First line only; read the complete Indications and dose section above.

50 micrograms twice daily

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 288

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.